Skip to main content

Full Alliance Group, Inc. (FAGI)

OTC Markets (US) Healthcare Drug Manufacturers - Specialty & GenericView data quality →
38.6Poor

ValueMarkers Composite Index

Top 4%#43,091 of 44,707
Slightly Undervalued

22% below intrinsic value ($0)

UndervaluedFair ValueOvervalued
Piotroski
2/9
Weak
Beneish
-2.79
Low Risk
Altman
-3.59
Distress
DCF Value
$0
Undervalued
ROIC
-3.8%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Full Alliance Group, Inc. (FAGI) — VMCI valuation read

Composite valuation read on FAGI: VMCI 39/100 against a Healthcare sector median of 50. The 11-point below-median print is the headline number for Full Alliance Group, Inc., and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.

Trailing 30-day insider activity for FAGI: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.

**Investor frame.** Value, quality, risk in three lines on FAGI: FAGI trades at 21.0x earnings, 17% above the Healthcare median of 18.0x; ROIC of 9.0% trails the Healthcare median (10.0%) by 1.0pp; net debt to EBITDA of 1.2x leaves covenant headroom. EV/EBITDA at 14.0x versus 12.0x for Healthcare closes the value frame.

FAGI fell 3.1% over the trailing 7 days, with a -21.8% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in FAGI’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.